Despite the different doses of semaglutide and tirzepatide and timepoints studied, the results of SURMOUNT-5 and the Truveta Research study were consistent, namely that tirzepatide-based medications performed better than semaglutide-based medications: SURMOUNT-5 study : At 72 weeks, weight loss was 20.2% for Zepbound (tirzepatide AOM) compared to 13.7% for Wegovy (semaglutide AOM)
Blood J Am Soc Hematol 100(3):897904 Maruoka H, Tanaka T, Murakami H, Tsuchihashi H, Toji A, Nunode M, Daimon A, Miyamoto S, Nishie R, Ueda S (2022) Cancer-specific miRNAs extracted from tissue-exudative extracellular vesicles in ovarian clear cell carcinoma
One of the most talked-about effects of glutathione IV therapy is its impact on skin tone
Pignatelli, P., Tellan, G., Marandola, M., Carnevale, R., Loffredo, L., Schillizzi, M., Proietti, M., Violi, F., Chirletti, P., and Delogu, G